hTERT DNA vaccine - Invectys

Drug Profile

hTERT DNA vaccine - Invectys

Alternative Names: hTERT DNA immunotherapy - Invectys; Human telomerase reverse transcriptase DNA vaccine - Invectys; INVAC-1

Latest Information Update: 14 Mar 2016

Price : $50

At a glance

  • Originator Invectys
  • Class Cancer vaccines; DNA vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Nov 2014 Preclinical trials in Solid tumours in France before November 2014 (Intradermal)
  • 18 Nov 2014 Invectys plans a phase I trial for Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater) in France (NCT02301754)
  • 01 Nov 2014 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in France (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top